AI Insight
Researchers conducted a first-in-human trial of PfSPZ-LARC2, a genetically modified malaria vaccine, in 75 children and adults in Burkina Faso. The vaccine uses live Plasmodium falciparum parasites engineered to replicate extensively in the liver but arrest before entering the bloodstream, mimicking the protective mechanism of the highly effective PfSPZ-CVac vaccine without requiring co-administration of chloroquine. The trial found no breakthrough blood-stage infections, similar safety profiles between vaccine and placebo groups, and promising immune responses, particularly in younger participants.
Why it matters
This vaccine approach could potentially achieve the WHO's goal of over 90% efficacy against malaria by providing a broader immune stimulus through late-stage liver parasite development while eliminating the need for antimalarial drug co-administration. The positive safety results in malaria-endemic populations, including young children who bear the highest disease burden, support advancement to Phase 2 efficacy trials.
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
The World Health Organization has called for malaria vaccines with > 90% efficacy against Plasmodium falciparum (Pf) infection. The live, non-attenuated PfSPZ-CVac (chloroquine) vaccine provides the strongest protection against controlled human malaria infection (CHMI). Its 100% protective efficacy at 12 weeks against genetically distant Pf stems from a highly amplified immune stimulus. After inoculation, each invading sporozoite (SPZ) replicates up to 50,000 times within a hepatocyte. Over six days of development, these parasites express thousands of distinct proteins, presenting a vast and diverse array of antigens to the host immune system. The late liver stage parasites then rupture into the bloodstream, where they are killed by the co-administered drug, chloroquine. To engineer a Pf parasite that develops to the late liver stage like PfSPZ-CVac (chloroquine), but then arrests before transitioning to the blood stage, two genes required for transition from non-pathogenic liver to pathogenic blood stages were identified and deleted, creating late-liver stage arresting, replication-competent (LARC) PfSPZ. In a first-in-human, randomized, double-blind, placebo-controlled clinical trial, we assessed PfSPZ-LARC2 Vaccine in 75 malaria-exposed Burkinabe 1- to 48-year-olds. No vaccine-strain breakthrough blood-stage infections were detected; safety and tolerability profiles were similar in vaccinees and placebo recipients; and the highest immunogenicity was observed in the youngest recipients. Based on these findings, PfSPZ-LARC2 Vaccine has progressed to Phase 2 testing with the goal of rapidly advancing this genetically attenuated whole parasite vaccine to licensure and deployment.